SCHEMBL25314972

SCHEMBL25314972

COCCNc1ccc(C(=O)O)cc1Cl

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 3/20 0.70
HCAR3 P49019 3/20 0.64
HPGD P15428 2/20 0.55
MAPT P10636 4/20 0.47
ALDH1A1 P00352 3/20 0.46
RAB9A P51151 1/20 0.46
TSHR P16473 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.46
PDK1 Q15118 1/20 0.46
PDK2 Q15119 1/20 0.46
PDK3 Q15120 1/20 0.46
PDK4 Q16654 1/20 0.46
PYGL P06737 2/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CSNK2A1 P68400 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
THRB P10828 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25314456 0.88 PTGER4 (0.56) PTGER4HCAR3HPGDMAPTALDH1A1
SCHEMBL25933704 0.84 PTGER4 (0.72) PTGER4HCAR3HPGDMAPTALDH1A1
SCHEMBL27041430 0.83 HCAR3 (0.61) PTGER4HCAR3HPGDMAPTALDH1A1
SCHEMBL23287173 0.82 PTGER4 (0.70) PTGER4HCAR3HPGDMAPTALDH1A1
SCHEMBL15774833 0.82 PTGER4 (1.00) PTGER4HCAR3HPGDMAPTALDH1A1
SCHEMBL19936478 0.81 PTGER4 (0.72) PTGER4HCAR3HPGDMAPTALDH1A1
SCHEMBL30780105 0.80 ALDH1A1 (0.66) HCAR3HPGDMAPTALDH1A1TSHR
SCHEMBL29114291 0.80 ALDH1A1 (0.66) HCAR3HPGDMAPTALDH1A1TSHR
SCHEMBL24214184 0.79 PTGER4 (0.65) PTGER4HCAR3MAPTALDH1A1RAB9A
SCHEMBL26988048 0.79 PTGER4 (0.65) PTGER4HCAR3HPGDMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416228-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK 2023-12-28 US disclosed
EP-4217355-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 Forkhead Biotherapeutics, inc. (US) 2023-08-02 EP disclosed
WO-2022066938-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 FORKHEAD BIOTHERAPEUTICS, INC. (US) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416228-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 FOXO1, FOXO3, GCKR PTGER4 4176/4885HCAR3 3858/4885HPGD 2722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.